Long-term Follow-up After Lamellar Keratoplasty in a Patient With Bilateral Idiopathic Corneal Keloid

Fukuda, Ken; Chikama, Tai-ichiro; Takahashi, Mutsuo; Nishida, Teruo

doi:10.1097/ico.0b013e31822018f2

Cited by 10 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial clinical trials with CAT-152 ameliorated scarring in patients who received trabeculectomy for intractable glaucoma 88,183 ; however, Phase III clinical trials were unable to validate such beneficial effects 184 . Tranilast, another incidental TGFβ inhibitor, has also been used successfully to reduce re-occurrence of corneal fibrosis, or primary pterygium, following corneal surgery 185 . It is possible that topical application of more-specific TGFβ inhibitors might also be used in treating corneal haze and conjunctival scarring (Table 1).…”

Section: Therapeutic Uses Of Tgfβ Signalling Inhibitionmentioning

confidence: 99%

Targeting the TGFβ signalling pathway in disease

Akhurst

Hata²

2012

Nat Rev Drug Discov

1,297

1,159

View full text Add to dashboard Cite

Many drugs that target transforming growth factor-β (TGFβ) signalling have disease applications. Preclinical and clinical studies indicate the utility of these agents in fibrosis and oncology, particularly in augmentation of existing cancer therapies, such as radiation and chemotherapy, as well as in tumour vaccines. There are also reports of specialized applications, such as the reduction of vascular symptoms of Marfan syndrome. Here, we consider why the TGFβ signalling pathway is a drug target, the potential clinical applications of TGFβ inhibition, the issues arising with anti-TGFβ therapy and how these might be tackled using personalized approaches to dosing, monitoring of biomarkers as well as brief and/or localized drug-dosing regimens.

show abstract

Section: Therapeutic Uses Of Tgfβ Signalling Inhibitionmentioning

confidence: 99%

Targeting the TGFβ signalling pathway in disease

Akhurst

Hata²

2012

Nat Rev Drug Discov

1,297

1,159

View full text Add to dashboard Cite

show abstract

“…Primary corneal keloid is caused by congenital diseases, such as Lowe's syndrome, 5 or may be of unknown etiology. 3 , 4 Therefore, primary corneal keloid is commonly seen earlier in life, and is sometimes present at birth. In contrast, secondary corneal keloid usually develops after penetrating trauma or surgery, 1 and secondary keloid thus sometimes needs to be distinguished from a hypertrophic scar.…”

Section: Discussionmentioning

confidence: 99%

“… 1 Most corneal keloids develop following trauma or disease of the cornea, although several cases of primary corneal keloid have been reported in patients without a history of surgery or trauma. 2 , 3 Surgical removal is required for visually significant corneal keloid, but the lesion tends to recur. 4 Fewer than 100 cases of corneal keloid have been reported and, to our knowledge, there have been no reports of corneal keloid after pterygium surgery.…”

Section: Introductionmentioning

confidence: 99%

A rare case of corneal keloid occurred 30 years after pterygium surgery and 3 years after cataract surgery

Miyamoto

Sakimoto

Homma

et al. 2020

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose We report a case of corneal keloid occurring 30 years after pterygium surgery and 3 years after cataract surgery. Observations The case of a 72-year-old man was referred because of blurred vision and corneal opacity in the right eye. Pterygium surgery had been performed on the right eye 30 years earlier, and bilateral cataract surgery had been done uneventfully via a temporal corneal incision 3 years ago. Deterioration of vision occurred in the right eye from 2 years ago. At the initial visit, his best corrected visual acuity (BCVA) was 20/2000 on the right. A white nodule that was well demarcated from the underlying stroma was seen on the right cornea. The nodule was excised by superficial keratectomy, with BCVA being 180/200 at 1 week after surgery. Pathological examination of the resected specimen revealed proliferation of fibroblasts and haphazard arrangement of collagen bundles, leading to a diagnosis of corneal keloid. Keloid-like lesion was also later noted in temporal corneal incision site of cataract surgery. Conclusions and importance This rare case of corneal keloid occurred as a late complication of pterygium surgery.

show abstract

“…Monoclonal antibodies have also been reported to be potential treatments for corneal scarring: TGF-β antagonists, such as TGF-β1 and β2 antibodies, have been shown to inhibit the formation of cutaneous scars in rodent wounds [ 277 ]. The use of Tranilast, a TGF-β inhibitor, reduced the re-occurrence of corneal fibrosis, or primary pterygium, a degenerative ocular surface disorder with fibrovascular growth of the bulbar conjunctiva onto the cornea [ 278 ].…”

Section: Therapeutic Uses Of Tgf-β Signaling Inhibitionmentioning

confidence: 99%

TGF-β Superfamily Signaling in the Eye: Implications for Ocular Pathologies

Hachana

Larrivée

2022

Cells

View full text Add to dashboard Cite

The TGF-β signaling pathway plays a crucial role in several key aspects of development and tissue homeostasis. TGF-β ligands and their mediators have been shown to be important regulators of ocular physiology and their dysregulation has been described in several eye pathologies. TGF-β signaling participates in regulating several key developmental processes in the eye, including angiogenesis and neurogenesis. Inadequate TGF-β signaling has been associated with defective angiogenesis, vascular barrier function, unfavorable inflammatory responses, and tissue fibrosis. In addition, experimental models of corneal neovascularization, diabetic retinopathy, proliferative vitreoretinopathy, glaucoma, or corneal injury suggest that aberrant TGF-β signaling may contribute to the pathological features of these conditions, showing the potential of modulating TGF-β signaling to treat eye diseases. This review highlights the key roles of TGF-β family members in ocular physiology and in eye diseases, and reviews approaches targeting the TGF-β signaling as potential treatment options.

show abstract

Long-term Follow-up After Lamellar Keratoplasty in a Patient With Bilateral Idiopathic Corneal Keloid

Cited by 10 publications

References 10 publications

Targeting the TGFβ signalling pathway in disease

Targeting the TGFβ signalling pathway in disease

A rare case of corneal keloid occurred 30 years after pterygium surgery and 3 years after cataract surgery

TGF-β Superfamily Signaling in the Eye: Implications for Ocular Pathologies

Contact Info

Product

Resources

About